| Annual · values | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Cash Flow | -79.95 M USD | -54.68 M USD | -31.98 M USD |
| Depreciation & Amortization | 248000 USD | 244000 USD | 157000 USD |
| Stock-Based Compensation | 8.68 M USD | 5.22 M USD | 2.04 M USD |
| Capital Expenditures | 1.93 M USD | 874000 USD | 129000 USD |
| Cash Flow from Investing | -83.70 M USD | -160.59 M USD | -30.93 M USD |
| Cash Flow from Financing | 189.59 M USD | 234.10 M USD | 69.22 M USD |
| Dividends Paid | — | — | — |
| Stock Buybacks | — | — | — |
| Free Cash Flow | -81.88 M USD | -55.55 M USD | -32.11 M USD |
Mbx Biosciences Inc. is a biopharmaceutical company focused on the research and development of innovative endocrine therapeutics. It strives to address unmet medical needs through pioneering treatments for endocrine disorders. The company's central aim is to develop precision endocrinology therapies, leveraging proprietary technologies to create treatment options that are more precise and effective for specific patient populations. Mbx Biosciences operates at the intersection of biotechnology and healthcare, significantly impacting the health sector by working towards solutions that can transform the management of hormonal disorders. In terms of market significance, Mbx Biosciences represents the advancing frontier of personalized medicine, emphasizing targeted therapies that promise improved outcomes and quality of life for patients suffering from conditions related to hormonal imbalances. By contributing to the biopharmaceutical landscape with innovative solutions, it holds a vital role in advancing both the scientific understanding and therapeutic interventions in endocrine health.